Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
OPERATING EXPENSES:
Research and development	$ 65,053	$ 44,027	$ 23,366
General and administrative	45,350	39,194	28,027
Total operating expenses	110,403	83,221	51,393
LOSS FROM OPERATIONS:	(110,403)	(83,221)	(51,393)
OTHER INCOME (EXPENSE), NET:
Other income, net	4,061	40	319
Foreign exchange gains (losses)	821	1,990	(11,702)
Fair value change of convertible notes	0	0	(1,041)
Fair value change of convertible notes - due to a related party	0	0	(730)
Benefit from R&D tax credit	14,424	9,648	4,245
Total other income (expense), net	19,306	11,678	(8,909)
Loss before income taxes	(91,097)	(71,543)	(60,302)
Income tax expense	(408)	(199)	(32)
Net loss	(91,505)	(71,742)	(60,334)
Other comprehensive loss:
Foreign exchange translation adjustment	(25,707)	(5,745)	14,683
Comprehensive loss	$ (117,212)	$ (77,487)	$ (45,651)
Net loss per share attributable to ordinary shareholders - basic (in dollars per share)	$ (2.16)	$ (1.79)	$ (3.55)
Net loss per share attributable to ordinary shareholders - diluted (in dollars per share)	$ (2.16)	$ (1.79)	$ (3.55)
Weighted average ordinary shares outstanding - basic (in shares)	42,436,292	39,997,587	16,991,664
Weighted average ordinary shares outstanding - diluted (in shares)	42,436,292	39,997,587	16,991,664